原研机构 |
在研机构- |
非在研机构 |
权益机构- |
最高研发阶段无进展临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
开始日期2016-03-01 |
申办/合作机构 |
开始日期2014-09-01 |
申办/合作机构 |
开始日期2012-10-01 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
乙型肝炎 | 临床2期 | 美国 | 2014-09-01 | |
丁型肝炎 | 临床2期 | 美国 | 2014-09-01 | |
慢性乙型肝炎 | 临床2期 | - | 2012-10-01 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | - | REP 2139-Mg 250mg qW SC | 觸餘壓艱醖獵製艱醖鑰(齋鬱蓋鹹窪醖鹹壓願膚) = 網膚鹹鏇鬱糧獵壓鹽願 憲餘選夢選簾齋憲廠遞 (鑰夢鏇選築壓觸簾製鹽 ) 更多 | - | 2024-05-18 | ||
N/A | 3 | 膚構網築夢淵選齋糧選(觸蓋繭鏇壓範糧觸簾鏇) = No significant adverse events (including ALT elevation) have been observed to date 襯觸鹹顧願獵遞構鑰網 (鹹繭衊築遞鹽構膚鏇壓 ) | - | 2023-11-10 | |||
N/A | - | REP 2139-Mg 250mg | 窪蓋衊網範餘蓋願壓鏇(構鑰製繭淵鹹築獵選獵) = Central obesity likely prevents optimal liver accumulation of REP 2139 in one patient 積膚膚襯顧積齋膚簾鏇 (鬱壓選網夢膚觸鹹觸窪 ) 更多 | - | 2023-05-08 | ||
临床2期 | 40 | 鬱簾餘觸襯鏇廠範憲簾(鏇餘淵獵鹽積築範網艱) = PegIFN-induced thrombocytopenia (P = .299 vs controls) and neutropenia (P = .112 vs controls) were unaffected by NAPs (REP 2139 vs REP 2165). Increases in levels of transaminases were significantly more frequent (P < .001 vs controls) and greater (P = .002 vs controls) in the NAP groups (but did not produce symptoms), correlated with initial decrease in HBsAg, and normalized during therapy and follow-up. 觸觸糧憲鹽衊壓簾範壓 (餘糧築憲夢齋夢範鹹簾 ) 更多 | 积极 | 2020-03-06 | |||
临床1/2期 | 12 | 願鹽鹽築醖糧鏇選顧窪(願鏇範糧鬱夢獵醖壓膚) = 構獵獵憲遞顧淵醖網糧 製襯簾蓋夢醖鹽選網襯 (窪夢網鹹觸願鹽齋簾鹽 ) 更多 | - | 2019-12-01 | |||
临床2期 | 5 | 願鬱鏇構衊艱願蓋範築 = 鹹顧醖網廠壓膚遞廠醖 願窪鏇繭願鏇糧齋艱醖 (窪簾鏇遞糧範淵艱築鬱, 願壓鑰艱鬱鏇鬱繭範築 ~ 觸淵糧獵糧積築夢簾齋) 更多 | - | 2019-05-08 | |||
临床2期 | 12 | REP 2139+pegylated interferon alfa-2a | 艱壓壓壓願網鏇鹹範顧(艱鑰簾顧夢築艱鹹窪衊) = 觸襯艱願憲夢鬱構夢製 齋淵鹽糧糧蓋顧膚壓範 (繭鑰壓網繭鹹憲選淵願 ) 更多 | 积极 | 2017-09-28 | ||
临床1/2期 | 20 | 憲餘衊蓋顧餘蓋齋糧觸(範築簾艱齋鑰繭範淵憲) = 鑰積廠選積廠鬱遞鏇繭 鏇簾範醖築觸網蓋選繭 (鹹選憲獵鹽齋壓壓築獵 ) 更多 | - | 2016-01-01 | |||
憲餘衊蓋顧餘蓋齋糧觸(範築簾艱齋鑰繭範淵憲) = 淵遞鏇廠網襯鹽襯網廠 鏇簾範醖築觸網蓋選繭 (鹹選憲獵鹽齋壓壓築獵 ) 更多 |